PRESS RELEASES AND SCIENTIFIC PUBLICATIONS

In the News

  • March 24

    Celsius Therapeutics Highlights Recent Accomplishments and Key Initiatives for 2022

    First Clinical Candidate, Anti-TREM1 Antibody for IBD, Identified Through Novel SCOPE Platform; Phase 1 Study Anticipated in Early 2023 $83 Million in Additional Financing CAMBRIDGE, Mass. – March 24, 2022 – Celsius Therapeutics, a biotechnology company leveraging its human tissue-based platform to develop precision medicines for patients with cancer and autoimmune disease, today provided a […]

Media inquiries: media@celsiustx.com
Investor inquiries: investor@celsiustx.com

PUBLICATIONS

page  
1 | 2
viewing
 per page